



Balfour Capital Group Quest Diagnostics Incorporated

Quest Diagnostics is one of the world's leading providers of diagnostic information services. It processes billions of clinical tests annually—including genetic, anatomic pathology, and drug diagnostics—and delivers actionable insights for healthcare providers, employers, clinical trials, and patients.

1. Top 5 Competitors

Key industry competitors include:

- LabCorp
- Sonic Healthcare
- Abbott Laboratories
- Thermo Fisher Scientific
- Invitae

2. Largest Institutional Shareholders

Institutional ownership hovers around ~90–92%. Top holders include:

- Vanguard Group Inc (≈12.5%)
- BlackRock, Inc.
- Price T. Rowe Associates
- State Street Corp
- JPMorgan Chase & Co

3. Management Team

- James E. Davis – Chairman, President & CEO (since Nov 1, 2022)
- Sam Samad – Executive VP & CFO
- Michael E. Prevoznik – Senior VP & General Counsel
- Catherine T. Doherty – EVP, Regional Businesses
- Adrienne Brott – SVP & Chief Quality & Regulatory Affairs Officer (appointed Jan 2025)
- Additional execs: Murali Balakumar, Garry Clark, Mark Delaney, Yuri Fesko, Karthik Kuppusamy, Michael Deppe, etc.



Balfour Capital Group Quest Diagnostics Incorporated

4. Revenue

- FY 2024: \$9.87 billion (+6.7% YoY)
- TTM (ending March 31, 2025): approximately \$10.15 billion (+9.4% YoY)
- Q1 2025: \$2.652 billion (+12.1%)

They reaffirmed FY 2025 guidance at \$10.7–10.85 billion in revenue

5. Institutions with Buy Recommendations:

At least one major institution that recently rated DGX as Buy:

- Jefferies (maintained Buy rating, set fresh target yesterday)

Additional broker sentiment data available below.

6. Analyst Sentiment Summary

- Recent tracker shows 9 buy, 10 hold, and 0 sell ratings with an average target price of ~\$183.92 (~5.5% upside).
- MarketBeat reports a consensus Moderate Buy (7 buy, 7 hold, 2 strong buy) at ~15–16 analysts; average target ~\$185.73.
- Overall tone is cautiously optimistic—analysts view DGX as a defensive “safe-haven” stock benefiting from stable demand and strong diagnostic volume trends

7. Insider Buying and Selling (Last 24 Months)

- Selling: Insider sales total ~\$145.1 K over the past 3 months; e.g. Mark Delaney sold ~60K shares at ~\$143 in July 2024 .
- Buying: Data is scarce; no clear evidence of open market insider purchasing in the past 3 months; sources say “insufficient data”.
- Additionally, Nasdaq insider report shows ~158K shares bought vs ~259K sold over 12 months, though the specifics are not fully transparent.